Emergent (EBS.US) gets $400M vaccine order, stock jumps over 8% at open

Emergent BioSolutions (EBS.US), a US monkeypox vaccine concept stock, soared more than 16% before the US stock market opened on Wednesday, after the company earlier said it had secured a portfolio of smallpox, smallpox and monkeypox vaccine orders worth about $400 million to be delivered in 2024 and 2025.

The biotechnology company said it had delivered customer orders worth nearly $210 million so far this year, involving its immunoglobulin products CNJ-016 and ACAM2000, which is its FDA-approved smallpox and monkeypox vaccine.

The company also committed to delivering orders related to CNJ-016 and ACAM2000 worth over $185 million in the rest of this year and in 2025.

The latest news comes as Africa is struggling to contain a persistent monkeypox outbreak, with the World Health Organization declaring the outbreak a "public health emergency of international concern" in August this year.

Chief Executive Joe Papa said: "Emergent remains a trusted partner for medical solutions to biodefense and global health preparedness."

He added: "These incremental orders demonstrate our continued leadership in helping to address serious viral threats such as smallpox and monkeypox."